Top 79 Contractors in NAICS 325411: Medicinal and Botanical Manufacturing, FY2022

Parent companies by net contract obligations Oct 1, 2021 – Sep 30, 2022 Code page on GovTribe

The top 10 won 100% of FY2022 NAICS 325411 contract dollars

Ranking facts

Contract obligations
$3,425,639,785 Net of deobligations, by contracts coded NAICS 325411
Contractors
89 Parent companies with an obligation
Largest contractor
Mckesson Corporation $2.91 billion, 85.0% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 79 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $2,912,387,412
Rank history: #1 in FY2021, #3 in FY2023, #64 in FY2024 and #39 in FY2025; unchanged since FY2021.
2 $359,505,122
Rank history: #2 in FY2021, #2 in FY2023, #1 in FY2024 and #1 in FY2025; unchanged since FY2021.
3 $58,093,696
Rank history: #3 in FY2021, #4 in FY2023, #3 in FY2024 and #3 in FY2025; unchanged since FY2021.
4
Amerisourcebergen Corporation Through Amerisourcebergen Drug Corp
$45,456,834
Rank history: not on the FY2021 list, #1 in FY2023, #2 in FY2024 and not on the FY2025 list; new.
5 $20,581,555
Rank history: #4 in FY2021, #7 in FY2023 and not on the FY2024–FY2025 lists; down 1 since FY2021.
6 $7,289,676
Rank history: #5 in FY2021, #6 in FY2023, #5 in FY2024 and #4 in FY2025; down 1 since FY2021.
7 $4,500,214
Rank history: #10 in FY2021, not on the FY2023 list, #6 in FY2024 and #16 in FY2025; up 3 since FY2021.
8 $2,465,591
Rank history: #7 in FY2021, #8 in FY2023, #8 in FY2024 and #7 in FY2025; down 1 since FY2021.
9 $1,764,829
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
10 $1,356,920
Rank history: #8 in FY2021, #9 in FY2023, #9 in FY2024 and #5 in FY2025; down 2 since FY2021.
11 $1,116,489
Rank history: #21 in FY2021, #17 in FY2023, #19 in FY2024 and #21 in FY2025; up 10 since FY2021.
12
Xellia Pharmaceuticals USA LLC
$1,022,563
Rank history: #57 in FY2021, #59 in FY2023 and not on the FY2024–FY2025 lists; up 45 since FY2021.
13
Hikma Pharmaceuticals PLC Through Hikma Pharmaceuticals USA Inc.
$859,726
Rank history: #22 in FY2021, #22 in FY2023, #63 in FY2024 and not on the FY2025 list; up 9 since FY2021.
14 $809,115
Rank history: #9 in FY2021, #52 in FY2023 and not on the FY2024–FY2025 lists; down 5 since FY2021.
15 $758,319
Rank history: #13 in FY2021 and not on the FY2023–FY2025 lists; down 2 since FY2021.
16 $687,343
Rank history: #11 in FY2021, #12 in FY2023, #11 in FY2024 and #13 in FY2025; down 5 since FY2021.
17 $644,456
Rank history: #16 in FY2021, #11 in FY2023, #30 in FY2024 and #19 in FY2025; down 1 since FY2021.
18 $611,569
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
19
Sagent Pharmaceuticals Inc.
$581,852
Rank history: #15 in FY2021, #26 in FY2023, #27 in FY2024 and #31 in FY2025; down 4 since FY2021.
20
Baxter International Inc. Through Baxter Healthcare Corporation
$561,094
Rank history: #59 in FY2021, #14 in FY2023, #48 in FY2024 and not on the FY2025 list; up 39 since FY2021.
21 $552,368
Rank history: #35 in FY2021 and not on the FY2023–FY2025 lists; up 14 since FY2021.
22 $548,920
Rank history: #26 in FY2021 and not on the FY2023–FY2025 lists; up 4 since FY2021.
23
Johnson & Johnson 2 awardees, including Johnson & Johnson Health Care Systems Inc.
$479,177
Rank history: #17 in FY2021, #13 in FY2023, #18 in FY2024 and #11 in FY2025; down 6 since FY2021.
24 $268,925
Rank history: #19 in FY2021, #24 in FY2023, #22 in FY2024 and #8 in FY2025; down 5 since FY2021.
25 $260,145
Rank history: #34 in FY2021, #15 in FY2023, #14 in FY2024 and #18 in FY2025; up 9 since FY2021.
26 $238,498
Rank history: #29 in FY2021, #20 in FY2023, #21 in FY2024 and #15 in FY2025; up 3 since FY2021.
27 $233,403
Rank history: #36 in FY2021, #31 in FY2023, #36 in FY2024 and #17 in FY2025; up 9 since FY2021.
28 $223,670
Rank history: #60 in FY2021 and not on the FY2023–FY2025 lists; up 32 since FY2021.
29
Cortec Group Inc. Through The Hygenic Corporation
$216,877
Rank history: #24 in FY2021 and not on the FY2023–FY2025 lists; down 5 since FY2021.
30 $205,078
Rank history: #25 in FY2021, #25 in FY2023, #28 in FY2024 and #24 in FY2025; down 5 since FY2021.
31 $193,320
Rank history: #23 in FY2021, #27 in FY2023, #29 in FY2024 and #27 in FY2025; down 8 since FY2021.
32 $184,436
Rank history: #20 in FY2021, #19 in FY2023, #26 in FY2024 and #20 in FY2025; down 12 since FY2021.
33 $145,073
Rank history: #32 in FY2021 and not on the FY2023–FY2025 lists; down 1 since FY2021.
34
Albany Molecular Research Inc. Through Curia Global Inc.
$106,395
Rank history: #12 in FY2021 and not on the FY2023–FY2025 lists; down 22 since FY2021.
35 $100,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
36 $97,015
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
37 $54,117
Rank history: #14 in FY2021, #10 in FY2023, #12 in FY2024 and not on the FY2025 list; down 23 since FY2021.
38 $53,499
Rank history: not on the FY2021 list, #33 in FY2023, #37 in FY2024 and #33 in FY2025; new.
39 $49,171
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #42 in FY2025; new.
40 $48,474
Rank history: #46 in FY2021, #38 in FY2023, #35 in FY2024 and #34 in FY2025; up 6 since FY2021.
41 $46,231
Rank history: #41 in FY2021 and not on the FY2023–FY2025 lists; unchanged since FY2021.
42
Jubilant Life Sciences Limited 2 awardees, including Jubilant Draximage Inc.
$39,075
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
43 $39,006
Rank history: not on the FY2021 list, #55 in FY2023, #68 in FY2024 and not on the FY2025 list; new.
44 $34,715
Rank history: #38 in FY2021, #41 in FY2023 and not on the FY2024–FY2025 lists; down 6 since FY2021.
45 $34,182
Rank history: #70 in FY2021, #34 in FY2023, #38 in FY2024 and #37 in FY2025; up 25 since FY2021.
46 $27,756
Rank history: #42 in FY2021, #42 in FY2023, #44 in FY2024 and #40 in FY2025; down 4 since FY2021.
47
X-GEN Pharmaceuticals Inc.
$25,892
Rank history: #49 in FY2021, #54 in FY2023 and not on the FY2024–FY2025 lists; up 2 since FY2021.
48 $24,614
Rank history: #62 in FY2021, #56 in FY2023, #34 in FY2024 and not on the FY2025 list; up 14 since FY2021.
49 $21,799
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
50 $19,913
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
51
UEI HBEFWR3J84M9
$17,307
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
52 $15,360
Rank history: not on the FY2021 list, #47 in FY2023, #59 in FY2024 and #53 in FY2025; new.
53 $14,355
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
54
Nanocellect Biomedical Inc
$13,750
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
55 $13,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
56 $12,376
Rank history: #64 in FY2021 and not on the FY2023–FY2025 lists; up 8 since FY2021.
57 $12,045
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
58
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG Through Heyltex Corporation
$11,185
Rank history: #30 in FY2021 and not on the FY2023–FY2025 lists; down 28 since FY2021.
59 $11,058
Rank history: #45 in FY2021 and not on the FY2023–FY2025 lists; down 14 since FY2021.
60
Object Pharma Inc. Through Metabiologics, Inc.
$11,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
61 $10,400
Rank history: #40 in FY2021 and not on the FY2023–FY2025 lists; down 21 since FY2021.
62 $7,801
Rank history: not on the FY2021 list, not on the FY2023 list, #55 in FY2024 and #41 in FY2025; new.
63
Alvogen Group Inc. Through Alvogen, Inc.
$7,546
Rank history: #72 in FY2021, not on the FY2023 list, #69 in FY2024 and not on the FY2025 list; up 9 since FY2021.
64
Avkare LLC
$5,400
Rank history: #47 in FY2021, #43 in FY2023, #39 in FY2024 and #36 in FY2025; down 17 since FY2021.
65 $4,706
Rank history: not on the FY2021 list, #48 in FY2023, #61 in FY2024 and not on the FY2025 list; new.
66
Theodor Wille Intertrade GMBH Through Atlantic Diving Supply, Inc.
$3,310
Rank history: not on the FY2021 list, #53 in FY2023 and not on the FY2024–FY2025 lists; new.
67 $2,713
Rank history: not on the FY2021 list, #57 in FY2023 and not on the FY2024–FY2025 lists; new.
68 $2,098
Rank history: #55 in FY2021, #61 in FY2023, not on the FY2024 list and #64 in FY2025; down 13 since FY2021.
69
Hikma Pharmaceuticals USA Inc.
$1,362
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
70 $1,275
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
71 $1,183
Rank history: #68 in FY2021 and not on the FY2023–FY2025 lists; down 3 since FY2021.
72 $784
Rank history: #78 in FY2021 and not on the FY2023–FY2025 lists; up 6 since FY2021.
73 $618
Rank history: #71 in FY2021 and not on the FY2023–FY2025 lists; down 2 since FY2021.
74 $611
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
75
Astrazeneca PLC Through Astrazeneca Pharmaceuticals LP
$500
Rank history: #76 in FY2021, #64 in FY2023, #73 in FY2024 and not on the FY2025 list; up 1 since FY2021.
76
Greenstone LLC
$216
Rank history: #73 in FY2021 and not on the FY2023–FY2025 lists; down 3 since FY2021.
77 $175
Rank history: not on the FY2021 list, #63 in FY2023 and not on the FY2024–FY2025 lists; new.
78 $70
Rank history: #81 in FY2021 and not on the FY2023–FY2025 lists; up 3 since FY2021.
79 $48
Rank history: #79 in FY2021 and not on the FY2023–FY2025 lists; unchanged since FY2021.
Show 54 more

79 of 89 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $3.43 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2022 ran Oct 1, 2021 – Sep 30, 2022. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2021. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2021 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 NAICS 325411 contractors in FY2022?

1. Mckesson Corporation ($2.91B), 2. Cencora, Inc. ($360M), 3. DMS Pharmaceutical Group Inc. ($58.1M), 4. Amerisourcebergen Corporation ($45.5M), 5. Amerisourcebergen Drug Corp ($20.6M), 6. Cardinal Health, Inc. ($7.29M), 7. Patterson Companies, Inc. ($4.5M), 8. Phoenix Textile Corporation ($2.47M), 9. Emergent Countermeasures International Ltd ($1.76M), 10. Fresenius Kabi LLC ($1.36M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work